Centre for Medical Imaging, University College London, London, UK.
Department of Clinical and Experimental Medicine, University of Surrey, Guildford, UK.
BMJ. 2018 Feb 14;360:k342. doi: 10.1136/bmj.k342.
To assess the association between anticoagulation, ischaemic stroke, gastrointestinal and cerebral haemorrhage, and all cause mortality in older people with atrial fibrillation and chronic kidney disease.
Propensity matched, population based, retrospective cohort analysis from January 2006 through December 2016.
The Royal College of General Practitioners Research and Surveillance Centre database population of almost 2.73 million patients from 110 general practices across England and Wales.
Patients aged 65 years and over with a new diagnosis of atrial fibrillation and estimated glomerular filtration rate (eGFR) of <50 mL/min/1.73m, calculated using the chronic kidney disease epidemiology collaboration creatinine equation. Patients with a previous diagnosis of atrial fibrillation or receiving anticoagulation in the preceding 120 days were excluded, as were patients requiring dialysis and recipients of renal transplants.
Receipt of an anticoagulant prescription within 60 days of atrial fibrillation diagnosis.
Ischaemic stroke, cerebral or gastrointestinal haemorrhage, and all cause mortality.
6977 patients with chronic kidney disease and newly diagnosed atrial fibrillation were identified, of whom 2434 were on anticoagulants within 60 days of diagnosis and 4543 were not. 2434 pairs were matched using propensity scores by exposure to anticoagulant or none and followed for a median of 506 days. The crude rates for ischaemic stroke and haemorrhage were 4.6 and 1.2 after taking anticoagulants and 1.5 and 0.4 in patients who were not taking anticoagulant per 100 person years, respectively. The hazard ratios for ischaemic stroke, haemorrhage, and all cause mortality for those on anticoagulants were 2.60 (95% confidence interval 2.00 to 3.38), 2.42 (1.44 to 4.05), and 0.82 (0.74 to 0.91) compared with those who received no anticoagulation.
Giving anticoagulants to older people with concomitant atrial fibrillation and chronic kidney disease was associated with an increased rate of ischaemic stroke and haemorrhage but a paradoxical lowered rate of all cause mortality. Careful consideration should be given before starting anticoagulants in older people with chronic kidney disease who develop atrial fibrillation. There remains an urgent need for adequately powered randomised trials in this population to explore these findings and to provide clarity on correct clinical management.
评估抗凝治疗与老年人伴心房颤动和慢性肾脏病患者的缺血性脑卒中、胃肠道出血和脑内出血以及全因死亡率之间的关联。
2006 年 1 月至 2016 年 12 月期间,采用倾向匹配、基于人群的回顾性队列分析。
来自英格兰和威尔士 110 家全科医生实践的几乎 273 万名患者的皇家全科医生学院研究和监测中心数据库人群。
年龄在 65 岁及以上,新诊断为心房颤动,估算肾小球滤过率(eGFR)<50mL/min/1.73m,采用慢性肾脏病流行病学合作研究肌酐方程计算。排除有既往心房颤动诊断或在之前 120 天内接受抗凝治疗的患者,以及需要透析和接受肾移植的患者。
在心房颤动诊断后 60 天内接受抗凝药物处方。
缺血性脑卒中、脑或胃肠道出血以及全因死亡率。
共确定了 6977 例患有慢性肾脏病和新发心房颤动的患者,其中 2434 例在诊断后 60 天内接受了抗凝治疗,4543 例未接受抗凝治疗。通过暴露于抗凝药物或不使用抗凝药物的倾向评分,对 2434 对患者进行了匹配,并进行了中位时间为 506 天的随访。接受抗凝治疗者的缺血性卒中和出血的粗发生率分别为每 100 人年 4.6 和 1.2,未接受抗凝治疗者的发生率分别为 1.5 和 0.4。接受抗凝治疗者的缺血性脑卒中、出血和全因死亡率的风险比分别为 2.60(95%置信区间 2.00 至 3.38)、2.42(1.44 至 4.05)和 0.82(0.74 至 0.91),与未接受抗凝治疗者相比。
对于同时患有心房颤动和慢性肾脏病的老年人给予抗凝药物治疗与缺血性脑卒中发生率和出血发生率增加相关,但全因死亡率降低。在慢性肾脏病患者中出现心房颤动时,在开始抗凝治疗之前应仔细考虑。在这一人群中,迫切需要进行足够的随机临床试验,以探索这些发现,并明确正确的临床管理。